ODC1 Mutation Treatment via DFMO Polyamine Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments are inadequate for identifying and managing pediatric developmental disorders associated with mutations in the ODC1 gene, leading to conditions like Bachmann-Bupp Syndrome and Snyder-Robinson syndrome, characterized by elevated polyamine levels and developmental delays.
Innovation Solution
Administering agents that inhibit the biosynthesis or activity of the ODC enzyme or polyamines, such as DFMO, to reduce polyamine levels and mitigate the symptoms of these disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If agents that inhibit ODC enzyme or polyamine biosynthesis are administered, then polyamine levels decrease and developmental delay symptoms improve, but treatment complexity and potential side effects increase
Solution Approach 1:
The patent changes the chemical parameters of the treatment by using DFMO (difluoromethylornithine), a specific inhibitor that targets the ODC enzyme pathway. This parameter change allows selective inhibition of polyamine biosynthesis in affected cells while minimizing broad toxic effects, thereby improving treatment reliability without proportionally increasing complexity
Solution Approach 2:
The patent introduces DFMO as an intermediary substance that mediates between the administration system and the ODC enzyme target. DFMO acts as a prodrug that is converted to fluoromethylornithine (FMK) in vivo, which then competitively inhibits ODC. This intermediary approach simplifies the treatment protocol while maintaining targeted effectiveness
2Object-affected harmful factors
If polyamine levels are reduced through inhibition, then developmental disorder symptoms are mitigated, but loss of beneficial polyamine functions occurs
Solution Approach 1:
The patent applies local quality by targeting polyamine inhibition specifically to cells with ODC1 gene mutations that exhibit pathological polyamine accumulation. Normal cells maintain their polyamine levels through regulatory mechanisms, thereby preserving beneficial functions in healthy tissues while eliminating harmful effects in affected cells
Solution Approach 2:
The patent employs partial action by using sub-maximal doses of DFMO that achieve sufficient inhibition of pathological polyamine synthesis without completely abolishing polyamine levels in all tissues. This partial inhibition approach mitigates harmful symptoms while preserving essential polyamine functions required for normal cellular processes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed method effectively decreases ODC enzyme activity and polyamine levels, potentially reversing or slowing the progression of developmental delays and associated symptoms in patients with ODC1 gene mutations.
Implementation Method 1
administering agents that inhibit the biosynthesis or activity of the ODC enzyme or polyamines
Data Source
AI summary
The invention provides methods for treating or preventing developmental disorders associated with mutations in the OCD1 gene.